Amneal Pharmaceuticals, Inc. (AMRX)

Amneal Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	5.9	-116.89	-83.99	-129.99	10.62	91.06
Depreciation & Amortization	240.48	236.19	229.4	240.18	233.41	235.39
Other Amortization	25.53	29.1	11.55	8.6	9.2	8.68
Loss (Gain) From Sale of Assets	-	-	-	-	-	-0.12
Asset Writedown & Restructuring Costs	22.78	0.92	66.93	24.08	28.55	36.72
Stock-Based Compensation	30.96	27.77	26.82	31.85	28.41	20.75
Other Operating Activities	172.47	122.08	142.05	-49.67	65.21	47.85
Change in Accounts Receivable	-138.83	-162.64	126.29	-79.72	-23.62	16.79
Change in Inventory	-118.83	-130.53	-126.18	-102.4	-49.02	-113.78
Change in Accounts Payable	69	235.14	-94.45	109.57	-43.93	0.31
Change in Other Net Operating Assets	18.29	53.96	47.15	12.6	-17.03	35.37
Operating Cash Flow	327.76	295.1	345.58	65.1	241.82	379
Operating Cash Flow Growth	4.77%	-14.61%	430.84%	-73.08%	-36.20%	22128.80%
Capital Expenditures	-78.14	-60.34	-46.8	-48.8	-50.94	-61.84
Sale of Property, Plant & Equipment	1.38	-	-	-	-	-
Cash Acquisitions	-	-	-	-84.71	-146.54	-251.36
Divestitures	7.01	11.99	-	-	-	-
Sale (Purchase) of Intangibles	-13.11	-14.65	-22.39	-41.8	-1.7	-4.35
Other Investing Activities	-	-	-	1	5	-
Investing Cash Flow	-82.87	-63	-69.19	-174.31	-194.18	-317.55
Short-Term Debt Issued	-	48	219	85	-	-
Long-Term Debt Issued	-	-	217.73	-	-	180
Total Debt Issued	2,918	48	436.73	85	-	180
Short-Term Debt Repaid	-	-44.2	-	-	-1	-
Long-Term Debt Repaid	-	-188.92	-414.08	-123.27	-78.18	-37.01
Total Debt Repaid	-2,861	-233.12	-414.08	-123.27	-79.18	-37.01
Net Debt Issued (Repaid)	57.4	-185.12	22.65	-38.27	-79.18	142.99
Issuance of Common Stock	1.56	1.15	0.45	0.66	0.85	0.32
Repurchase of Common Stock	-22.34	-7.95	-2.38	-3.57	-2.66	-0.86
Other Financing Activities	-119.23	-19.88	-233.3	-65.44	-57.13	-10.64
Financing Cash Flow	-82.61	-211.79	-212.57	-106.62	-138.12	131.81
Foreign Exchange Rate Adjustments	-2.21	-1	0.07	-5.68	0.1	1.04
Net Cash Flow	160.06	19.31	63.88	-221.51	-90.38	194.3
Free Cash Flow	249.62	234.76	298.78	16.3	190.88	317.17
Free Cash Flow Growth	-5.15%	-21.43%	1732.42%	-91.46%	-39.82%	-
Free Cash Flow Margin	8.51%	8.40%	12.48%	0.74%	9.12%	15.92%
Free Cash Flow Per Share	0.78	0.76	1.70	0.11	1.26	2.13
Cash Interest Paid	217.05	263.52	192.81	142.72	121.75	130.19
Cash Income Tax Paid	23.74	15.22	2.5	12.65	15.56	-100.14
Levered Free Cash Flow	218.71	253.45	307.26	120.14	217.65	153.82
Unlevered Free Cash Flow	347.25	385.98	427.36	210.53	293.65	236.39
Change in Working Capital	-170.37	-4.07	-47.19	-59.95	-133.59	-61.32

Updated Oct 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q